Interleaving Stimulation in Parkinson Disease: Interesting to Whom?
Carregando...
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2019
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Citação
WORLD NEUROSURGERY, v.130, p.E786-E793, 2019
Resumo
BACKGROUND: Interleaving stimulation (ILS) is a stim-ulation strategy that can help the physician manage more challenging cases of patients with deep brain stimulation (DBS) for Parkinson disease (PD). It consists of altering 2 different programs on the electrode with the same frequency. OBJECTIVES: Our objective was to overview our patients experience with ILS and explore clinical scenarios in which ILS should be considered when programming DBS in patients with PD. METHODS: We retrospectively reviewed medical charts from 120 patients with PD treated with DBS between 2011 and 2018. RESULTS: Eighteen patients received ILS. One was excluded because of the medical chart was incomplete. The remaining 17 patients had subthalamic nucleus DBS (n = 14) and globus pallidus internus DBS (n = 3). Eight patients (47%) received ILS to improve rigidity and bradykinesia, 4 to improve dyskinesias, 4 because of refractory tremor, and 1 for gait management. Until the end of data collection, 13 of 17 patients (70%) were still on ILS, with a mean duration time of 28.8 months (range, 2-44 months) Four patients reported no benefit from ILS and had their program changed. CONCLUSIONS: Overall, ILS is useful 1) to use 2 contacts optimally improve 2 specific symptoms but have different therapeutic windows; 2) to avoid side effects related to current spreading to nearby areas; 3) to increase frequency in a small region; or 4) to stimulate a larger target area.
Palavras-chave
Deep brain stimulation, Interleaving, Parkinson disease
Referências
- Barbe MT, 2014, NEUROLOGY, V82, P614, DOI 10.1212/WNL.0000000000000127
- Baumann CR, 2012, MOVEMENT DISORD, V27, P1700, DOI 10.1002/mds.25221
- Birdno MJ, 2008, NEUROTHERAPEUTICS, V5, P14, DOI 10.1016/j.nurt.2007.10.067
- Blomstedt P, 2018, J NEUROL NEUROSUR PS, V89, P710, DOI 10.1136/jnnp-2017-317219
- Brosius SN, 2015, PARKINSONISM RELAT D, V21, P1469, DOI 10.1016/j.parkreldis.2015.09.047
- Ferraye MU, 2010, BRAIN, V133, P205, DOI 10.1093/brain/awp229
- Guridi J, 2008, NEUROSURGERY, V62, P311, DOI 10.1227/01.NEU.0000297052.97282.CF
- Herzog J, 2007, MOVEMENT DISORD, V22, P679, DOI 10.1002/mds.21387
- Jaccard P, 1912, NEW PHYTOL, V11, P37, DOI 10.1111/J.1469-8137.1912.TB05611.X
- Kern DS, 2018, STEREOT FUNCT NEUROS, V96, P379, DOI 10.1159/000494983
- Kovacs N, 2012, MOVEMENT DISORD, V27, P163, DOI 10.1002/mds.23962
- Krack P, 1999, BRAIN, V122, P1133, DOI 10.1093/brain/122.6.1133
- Maks CB, 2009, J NEUROL NEUROSUR PS, V80, P659, DOI 10.1136/jnnp.2007.126219
- Miocinovic S, 2014, PARKINSONISM RELAT D, V20, P1434, DOI 10.1016/j.parkreldis.2014.10.011
- Moro E, 2002, NEUROLOGY, V59, P706, DOI 10.1212/WNL.59.5.706
- Moro E, 2010, BRAIN, V133, P215, DOI 10.1093/brain/awp261
- Nishikawa Y, 2010, NEUROL MED-CHIR, V50, P257, DOI 10.2176/nmc.50.257
- Okun MS, 2005, ARCH NEUROL-CHICAGO, V62, P1250, DOI 10.1001/archneur.62.8.noc40425
- Peppe A, 2004, J NEUROSURG, V101, P195, DOI 10.3171/jns.2004.101.2.0195
- Picillo M, 2016, BRAIN STIMUL, V9, P425, DOI 10.1016/j.brs.2016.02.004
- Ramirez-Zamora A, 2015, J NEUROL, V262, P578, DOI 10.1007/s00415-014-7605-3
- Rodriguez-Oroz MC, 2012, MOVEMENT DISORD, V27, P1718, DOI 10.1002/mds.25214
- Tsukada R, 2017, NEUROL CLIN NEUROSCI, V5, P32, DOI 10.1111/ncn3.12085
- Volkmann J, 2006, MOVEMENT DISORD, V21, pS284, DOI 10.1002/mds.20961
- Wagle Shukla Aparna, 2016, IEEE Rev Biomed Eng, V9, P219, DOI 10.1109/RBME.2016.2588399
- Weiss D, 2013, BRAIN, V136, P2098, DOI 10.1093/brain/awt122
- Weiss D, 2011, J NEUROL, V258, P1183, DOI 10.1007/s00415-011-5906-3
- Wojtecki L, 2011, PARKINSONISM RELAT D, V17, P293, DOI 10.1016/j.parkreldis.2010.12.005
- ZHANG SZ, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005575